Trial reportInvestigational new drugs2007
A phase II and pharmacological study of the matrix metalloproteinase inhibitor (MMPI) COL-3 in patients with advanced soft tissue sarcomas.
Trial report in Investigational new drugs, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 60 citations in OpenAlex.
- Matrix Metalloproteinase Inhibition in Melanoma.Experimental dermatology · 2026Review
- Recent advances in the design and development of small-molecule MMP-2 inhibitors.Future medicinal chemistry · 2025Review
- Article
- Computational drug discovery for castration-resistant prostate cancers through in vitro drug response modeling.Proceedings of the National Academy of Sciences of the United States of America · 2023Article
- Antitumor Therapy Targeting the Tumor Microenvironment.Journal of oncology · 2023Review
- Article
- The Pharmacological TAILS of Matrix Metalloproteinases and Their Inhibitors.Pharmaceuticals (Basel, Switzerland) · 2020Review
- Targeting the Tumor Microenvironment in Neuroblastoma: Recent Advances and Future Directions.Cancers · 2020Review
- Determinants and Functions of CAFs Secretome During Cancer Progression and Therapy.Frontiers in cell and developmental biology · 2020Review
- Microglial Cells Impact Gut Microbiota and Gut Pathology in Angiotensin II-Induced Hypertension.Circulation research · 2019Article
- Targeting Tumor Microenvironment for Cancer Therapy.International journal of molecular sciences · 2019Review
- Engineering of TIMP-3 as a LAP-fusion protein for targeting to sites of inflammation.Journal of cellular and molecular medicine · 2019Article
- Tetracycline repurposing in neurodegeneration: focus on Parkinson's disease.Journal of neural transmission (Vienna, Austria : 1996) · 2018Review
- Matrix metalloproteinases in the brain and blood-brain barrier: Versatile breakers and makers.Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism · 2016Review
- Candidate prognostic markers in breast cancer: focus on extracellular proteases and their inhibitors.Breast cancer (Dove Medical Press) · 2014Review
- Current and emerging therapeutic strategies for preventing inflammation and aggrecanase-mediated cartilage destruction in arthritis.Arthritis research & therapy · 2014Review
- Potent tumor targeting drug release system comprising MMP-2 specific peptide fragment with self-assembling characteristics.Drug design, development and therapy · 2014Article
- Matrix metalloproteinases as potential targets in the venous dilation associated with varicose veins.Current drug targets · 2013Review
- Matrix metalloproteinase inhibitor COL-3 prevents the development of paclitaxel-induced hyperalgesia in mice.Medical principles and practice : international journal of the Kuwait University, Health Science Centre · 2013Article
- Targeting angiogenesis for treatment of human cancer.Indian journal of pharmaceutical sciences · 2013Article
Corrections and comments
- Erratum issuedCopper, Joshua [corrected to Cooper, Joshua]
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This phase II study evaluated the antitumor activity of the tetracycline analog COL-3, a potent inhibitor of metalloproteinases (MMPs), particularly MMP-2 and MMP-9, on a continuous oral schedule at a dose of 50 mg/m2 daily in patients with advanced and/or metastatic soft tissue sarcoma (STS). The principal endpoints were the rate of objective tumor regression and the proportion of patients who did not experience disease progression during the first 8 weeks of treatment. Other study objectives included an assessment of pharmacology of COL-3, time to progression (TTP), and overall survival. A Simon two-stage design with multinomial stopping rule was employed, with 15 patients enrolled during the first stage of the study. Although COL-3 was generally well-tolerated, there were no objective responses and 5(33%) patients experienced disease progression during the first 8 weeks of treatment, which exceeded the criteria established a priori with regard to pursuing further evaluations of COL-3 in STS. The median values for TTP and survival were 109 and 279 days, respectively. Based on these results, further studies of COL-3 on this administration schedule in patients with STS are not warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.